Articles tagged with Prostate Cancer
A study found that PSMA PET/CT can accurately diagnose advanced prostate cancer in elderly patients without the need for a biopsy. The procedure reduced the number of biopsies and associated complications, while providing clinical suspicion-based staging data.
Researchers have found a promising new mechanism to target aggressive forms of prostate cancer, where the LSD1 protein is involved. By inhibiting LSD1, the tumor suppressor gene p53 can be reactivated, leading to suppression of tumor growth.
A Harvard T.H. Chan School of Public Health study found that chronic exposure to fine particulate air pollutants (PM2.5) and nitrogen dioxide (NO2) increases the risk of colorectal and prostate cancers in older adults. NO2 exposure was also associated with an increased risk of breast cancer, while PM2.5 exposure had mixed results.
Researchers found that hospitals treating a higher volume of patients with aggressive prostate cancer have better outcomes, indicating a possible association between expertise and resource availability. Further investigation is needed to understand the specific causes behind this relationship.
A meta-analysis of multiple studies found no association between depression and anxiety and most types of cancer. However, the study found a link between depression and anxiety with a 6% higher risk of developing lung cancer and smoking-related cancers.
A study by Harvard T.H. Chan School of Public Health found that chronic exposure to fine particulate air pollutants (PM2.5) and nitrogen dioxide (NO2) may increase non-lung cancer risk in older adults, with significant associations with colorectal and prostate cancers.
A study published in JAMA Network Open found that providing equal access to healthcare reduces disparities in treatment outcomes between Black and white patients with advanced prostate cancer. The research suggests that addressing racial disparities in healthcare may improve survival rates for this patient group.
PSMA PET imaging provides prognostic information on cancer recurrence risk before treatment, improving personalized treatments and guiding surgical plans. The tool outperforms current standard tests in predicting biochemical recurrence, a critical factor in determining cancer-specific mortality.
A new multiplex assay has been developed to assess activated p300/CBP in circulating prostate tumor cells, revealing correlations with clinical outcomes and potential therapeutic targets for castration-resistant prostate cancer. The study found that patients with upregulated p300/CBP activity had shorter response times to ARSI therapy.
A study of 29 clinical trials found that MRg-A-SBRT significantly reduces urinary and bowel side effects in prostate cancer patients, with a 44% reduction in urinary and 60% reduction in bowel side effects. This technique uses imaging technology to accurately aim radiation beams at the prostate while avoiding nearby tissue.
A new study published in JAMA Network Open found that Black Americans are more likely to trust videos about prostate cancer presented by a Black doctor. The study, led by researchers at NYU Grossman School of Medicine, involved over 2,900 participants and showed that racial diversity among healthcare providers is crucial for improving ...
Researchers at the University of South Australia have discovered three new biomarkers for prostate cancer that can accurately visualize and grade the disease. The breakthrough technology will enable clinicians to determine which patients require immediate treatment, potentially saving thousands of lives annually.
Sylvester Comprehensive Cancer Center researchers developed a first-of-its-kind orally administered drug Platin-L to disrupt prostate cancer cells' metabolism and deliver cisplatin directly into treatment-resistant cancer cells. The study showed that Platin-L is safe and effective in shrinking treatment-resistant cancers.
Researchers have developed a new therapy that disrupts prostate cancer cell metabolism and releases cisplatin, causing cells to die. In mouse models, the treatment shrunk tumors substantially, with no peripheral neuropathy or weight loss.
A new study reveals Indigenous men in Canada are more likely to be diagnosed with advanced prostate cancer and experience cancer spread, despite universal healthcare access. Researchers identify key infrastructure changes needed to improve screening and treatment outcomes.
A study found that 79 patients experienced high financial toxicity, with 89% reporting hardship, and highlighted patient characteristics and coping strategies. Patients made personal sacrifices to remain compliant with treatments, including reducing spending and borrowing money.
A new study published in NEJM Evidence validates a predictive AI biomarker for androgen deprivation therapy (ADT) benefit in prostate cancer. The study found that personalized use of short-term ADT could improve patient outcomes in men with predominantly intermediate-risk prostate cancer.
A new AI model has been developed to help doctors determine the extent of cancer within the prostate gland, improving the effectiveness of focal therapy. The model was found to be more accurate than magnetic resonance imaging (MRI) in predicting tumor margins, reducing the chance of cancer recurrence.
Researchers have developed a new technique to generically treat several kinds of cancer, showing tumors grew almost three times less and survival rates reached 100% after just one injection. The method targets cancer cells with alpha radiation, sparing healthy tissue.
A study found that monitoring early-response biomarkers enables personalized dosing in prostate cancer treatment, improving patient outcomes. The approach allowed patients to take
A new prostate cancer treatment combining enzalutamide and talazoparib has been approved by the FDA, offering improved patient outcomes. The treatment was found to decrease the risk of cancer progression by 55% in a phase 3 trial.
A randomized phase II study found that adding metformin to androgen deprivation therapy did not reduce the risk of metabolic syndrome or improve PSA response in patients with advanced prostate cancer. Metformin showed some antitumor effects through mTOR inhibition, but these were not significant.
The study found no improvement in freedom from progression rates for patients receiving combined EBRT and brachytherapy (COMBO) compared to those receiving brachytherapy alone (BT). Late adverse events were significantly increased in the COMBO arm, favoring BT as a standard of care for intermediate-risk prostate cancer patients.
A new study found significant reductions in breast, colorectal and prostate cancers as well as melanoma diagnoses in Alberta during the COVID-19 pandemic. Diagnoses dropped by 43% for melanoma, 36% for colorectal and prostate, and 33% for breast cancer during the 'state of emergency' phase.
A study has identified a potential treatment target for prostate cancer that is resistant to hormone therapy, a protein modification involving TRAF4. The researchers found that TRAF4 promotes the spread of cancer and may be associated with a new treatment option for patients.
Research in mice suggests that prostate cancer cells adapt to testosterone-deprivation therapy by producing cholesterol and generating their own testosterone. Treating aggressive tumors with inhibitors slows tumor growth. The study also points to a possible drug combination and sheds light on racial disparities in prostate cancer.
A research team has identified a previously unknown weak spot in prostate cancer cells that could lead to new therapeutic approaches for other types of cancer. The study found that inhibiting this process can reduce cancer growth without affecting normal cell growth.
A recent study found that American Indian and Alaska Native men are significantly less likely to receive prostate-specific antigen (PSA) testing and digital rectal exams from primary care providers compared to White men. This disparity results in poorer prostate cancer outcomes, particularly for men between 50-59 years old.
A large genome-wide association study identified novel PSA-associated variants and developed a polygenic score to correct for genetic variations in PSA levels. This approach improved biopsy referral decisions, reducing unnecessary procedures while detecting more aggressive tumors.
The SWOG Cancer Research Network will present 30 abstracts at the ASCO 2023 annual meeting, highlighting primary results from trials S1011, S1826, S1714, and S1929. Additionally, analysis from the S1609 DART trial will be shared publicly during the meeting.
A large-scale retrospective analysis by Sylvester Comprehensive Cancer Center researchers found that differences in care, rather than genetics, likely explain disparities in advanced prostate cancer between men of African and European ancestries. Men of African ancestry are less likely to receive comprehensive genetic profiling and tar...
Researchers tracked immune cell clusters in the aging mouse prostate using highly multiplexed immune profiling. Early adulthood sees myeloid cells, while between 6-12 months old, there's a profound shift to T and B lymphocyte-dominance. The study reveals new insight into prostatic inflammaging and the window for interventions.
Researchers from the UCLA Jonsson Comprehensive Cancer Center are presenting findings on combination therapies for breast cancer and a potential new treatment for patients with recurrent glioma. A phase 3 study evaluating vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation is also be...
Experts warn that shared decision-making policies for prostate cancer testing lead to high rates of unnecessary testing and harm, particularly in older men and those from disadvantaged areas. A comprehensive risk-based approach or restricting testing to symptomatic cases could reduce overdiagnosis and overtreatment.
Research suggests weight gain between ages 17-29 increases aggressive prostate cancer risk by 13% and fatal prostate cancer risk by 27%. Preventing weight gain in young adulthood may reduce prostate cancer risk. The study analyzed data from over 250,000 Swedish men, finding a significant association between weight gain and prostate can...
Overweight and obesity in early adulthood are associated with increased risks of colorectal cancer and non-colorectal gastrointestinal cancers. The study highlights the need for further exploration into the mechanisms driving these associations.
A new study found a strong link between bone biomarkers and survival rates in men with hormone-sensitive prostate cancer treated with hormone therapy. The research, published in European Urology, analyzed results from a large clinical trial and found that elevated bone biomarkers were associated with an increased risk of death.
Moffitt researchers develop CAR T cells that target prostate cancer biomarker PSCA, killing cancer cells and preserving bone health. Zoledronate treatment enhances antitumor activity with minimal toxicity.
A case series study found prostate cancer occurs in transgender women, contrary to previous reports suggesting rarity. Rates were lower than anticipated based on prior male veteran prostate cancer incidence estimates.
A first-of-its-kind study has estimated that transgender women taking estrogen are at a higher risk for prostate cancer, with 14 cases per 10,000 people. The study found disparities in diagnosis rates among different racial groups.
The study found that dose-escalated radiotherapy with short-term androgen deprivation therapy improved rates of biochemical failure, distant metastases, and prostate cancer-specific mortality. However, the trial did not meet its primary endpoint of improving overall survival for men with intermediate-risk prostate cancer.
A recent study published in Journal of Clinical Oncology found that dose-escalated radiotherapy with short-term androgen deprivation therapy showed no significant impact on urinary or bowel quality of life for men with intermediate-risk prostate cancer. However, the treatment did significantly decrease hormone and sexual quality of lif...
A new PSMA PET scoring system, the tumor-to-salivary gland ratio (PSG score), can predict patient response to <sup> 177 </sup> Lu-PSMA therapy. Patients with high PSG scores had longer PSA progression-free survival and overall survival rates.
A study of 15,296 men found that a healthy Mediterranean or Prudent diet had no impact on prostate cancer risk, while an unhealthy Western diet may increase the risk of aggressive tumors. The findings suggest avoiding Western-style diet products and adopting Mediterranean diet habits could help prevent aggressive prostate cancer.
A study published in Cancer Research Communications found that vitamin D receptor genetic differences in African American men may make them more vulnerable to prostate cancer. The researchers suggest that revised nutritional guidelines for vitamin D intake may be necessary to address these disparities.
A new study reveals that the HOXB13 protein regulates PSMA expression, even when the androgen receptor is absent, and identifies amino acids that are upregulated in low-PSMA tumors. This complex system of PSMA control has multiple subtypes, suggesting optimally targeted therapies.
Enoblituzumab, a monoclonal antibody, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body. The drug targets B7-H3 protein overexpressed on prostate cancer cells, blocking immune system inhibition and triggering tumor cell destruction by activating immune cells.
A recent study identified novel genes that influence PARP inhibitor response in prostate cancer, including MMS22L and RNASEH2B. The research found that loss of CHEK2, a previously approved biomarker, confers resistance to PARP inhibition, highlighting the need for comprehensive genomic analysis to improve treatment decisions.
A study published in JAMA Internal Medicine found that more US prostate cancer patients are choosing active surveillance, a preferred treatment option for low-risk cancers. The study also highlights disparities by race, ethnicity, income, and rurality in receiving active surveillance.
A rapid genetic testing model identified pathogenic variants in 51 patients with advanced prostate cancer, leading to discussions of possible treatment changes for 22 patients. The streamlined approach detected actionable gene variants eligible for newer targeted therapies in nearly half of patients with these variants.
A new finger-prick test for Trichomonas vaginalis has been developed by Washington State University researcher John Alderete. The test detects an antibody specific to the organism and provides rapid, affordable results, making it a potential game-changer in the fight against this prevalent but neglected STI.
ENZAMET, a new drug combination, has shown significant improvement in survival rates for men with advanced prostate cancer. After five years, the treatment led to a 67% survival rate, compared to 57% for standard therapy.
Current radiotherapy contouring guidelines often miss lesions in the prostate bed, leading to unnecessary tissue irradiation. PSMA PET mapping reveals that nearly a third of patients experience disease progression within 10 years after radical prostatectomy.
A new study from McGill University reveals that every day Canadians are exposed to Bisphenol S (BPS) in fresh foods due to chemical migration from packaging materials. High concentrations of BPS were found on thermal food labels, exceeding the European Union's regulatory limit.
The ProtecT trial found that active monitoring of prostate cancer has the same high survival rates after 15 years as radiotherapy or surgery. Men on active monitoring were more likely to see their cancer progress, but this didn't reduce their likelihood of survival.
A new technique involving a small flap in the peritoneum can reduce postoperative complications in prostate cancer surgery by allowing lymphatic fluid to escape and be absorbed. The study found that this technique significantly reduced the incidence of lymphocele, a common complication where lymphatic fluid collects in the pelvis.
A recent study published in JNCCN found that the lack of genomic research for people with African ancestry is hindering efforts to reduce disparities in prostate cancer outcomes. The researchers evaluated molecular genetic results for 113 Black South African men diagnosed with advanced prostate cancer, identifying 17 pathogenic and pot...
A trial using PSMA-PET/CT scans has shown that clinicians changed their treatment plans for patients with clinically significant prostate cancer in 19% of cases, helping to detect more cancers. The technique was found to be beneficial in high-risk patients but also led to false positives requiring further investigations.
A Mediterranean diet rich in colourful fruits and vegetables helps prevent prostate cancer and speeds up recovery after radiation treatment. Foods such as tomatoes, melons, and nuts are particularly beneficial due to their high levels of lycopene and selenium.
A new study suggests that digital rectal examination (DRE) is not a reliable screening tool for early prostate cancer detection. Researchers found that DRE missed many cancers in their early stages, with only 3 out of 57 suspicious cases detected. This method was compared to PSA testing, which detected four times more prostate cancers.